Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Key Highlights
- ➤Sanofi option triggers Recursion’s $10 million milestone payment.
- ➤Recursion receives $144 million in total upfront and milestone payments.
- ➤Recursion remains eligible for over $300 million in additional milestones.
- ➤Sanofi adds potential first-in-class oral immunology candidate to its pipeline.
- ➤Phase 1 trials are expected to begin in 2027, funded and led by Sanofi.
Expert Statements
Najat Khan, President and Chief Executive Officer of Recursion Pharmaceuticals
“The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines. Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline. With additional programs advancing across our collaboration, this milestone is another important demonstration of how our platform can translate computational capabilities into differentiated medicines — and do so repeatedly.”
Alyssa Johnsen, Therapeutic Area Head, Development, Immunology & Inflammation, Sanofi
“By combining Sanofi's drug discovery and clinical and translational knowledge in immunology with Recursion's AI-driven platform, we were able to move with speed and precision in a space where that balance is notoriously hard to achieve. This new development candidate has potential to deliver a differentiated oral medicine with highly selective dual targeting that could be a meaningful advance for people living with inflammatory diseases who still lack adequate treatment options.”
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration.
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for more than $300 million in additional milestones under the program, with double digit royalties on net product sales, if approved.
Get started
Create a free account to read the full story.